A new trading day began on Monday, with Ascendis Pharma A/S ADR (NASDAQ: ASND) stock price down -3.56% from the previous day of trading, before settling in for the closing price of $126.51. ASND’s price has ranged from $90.13 to $161.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 182.00% over the past five years. Meanwhile, its annual earnings per share averaged 16.08%. With a float of $59.25 million, this company’s outstanding shares have now reached $59.76 million.
In terms of profitability, gross margin is 85.56%, operating margin of -111.27%, and the pretax margin is -151.23%.
Ascendis Pharma A/S ADR (ASND) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Ascendis Pharma A/S ADR is 0.86%, while institutional ownership is 105.24%.
Ascendis Pharma A/S ADR (ASND) Latest Financial update
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -1.54 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.35 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 16.08% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 38.10% during the next five years compared to -19.87% drop over the previous five years of trading.
Ascendis Pharma A/S ADR (NASDAQ: ASND) Trading Performance Indicators
Here are Ascendis Pharma A/S ADR’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 0.84. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 20.57.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -8.10, a number that is poised to hit -1.32 in the next quarter and is forecasted to reach -3.79 in one year’s time.
Technical Analysis of Ascendis Pharma A/S ADR (ASND)
Ascendis Pharma A/S ADR (NASDAQ: ASND) saw its 5-day average volume 0.81 million, a positive change from its year-to-date volume of 0.45 million. As of the previous 9 days, the stock’s Stochastic %D was 34.61%. Additionally, its Average True Range was 5.47.
During the past 100 days, Ascendis Pharma A/S ADR’s (ASND) raw stochastic average was set at 24.55%, which indicates a significant decrease from 26.42% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 31.74% in the past 14 days, which was lower than the 45.00% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $132.40, while its 200-day Moving Average is $137.02. Nevertheless, the first resistance level for the watch stands at $125.98 in the near term. At $129.97, the stock is likely to face the second major resistance level. The third major resistance level sits at $132.59. If the price goes on to break the first support level at $119.37, it is likely to go to the next support level at $116.75. The third support level lies at $112.76 if the price breaches the second support level.
Ascendis Pharma A/S ADR (NASDAQ: ASND) Key Stats
With a market capitalization of 7.29 billion, the company has a total of 60,642K Shares Outstanding. Currently, annual sales are 288,670 K while annual income is -521,070 K. The company’s previous quarter sales were 38,770 K while its latest quarter income was -117,790 K.
